首页> 外文OA文献 >PITAVASTATIN 4 MG PROVIDES SIGNIFICANTLY GREATER REDUCTION IN LDL-C COMPARED TO PRAVASTATIN 40 MG WITH NEUTRAL EFFECTS ON GLUCOSE METABOLISM: PRESPECIFIED SAFETY ANALYSIS FROM THE SHORT-TERM PHASE 4 PREVAIL US TRIAL IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

【2h】

PITAVASTATIN 4 MG PROVIDES SIGNIFICANTLY GREATER REDUCTION IN LDL-C COMPARED TO PRAVASTATIN 40 MG WITH NEUTRAL EFFECTS ON GLUCOSE METABOLISM: PRESPECIFIED SAFETY ANALYSIS FROM THE SHORT-TERM PHASE 4 PREVAIL US TRIAL IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

机译：与帕伐他汀40 MG相比，匹伐他汀4 MG的LDL-C显着降低，而对胰高血糖素的代谢有中性影响：从短期4期开始的安全性分析已经明确，美国典型的患者患病的原因是：

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Kryzhanovski Vladimir; Morgan Roger; Sponseller Craig; Davidson Michael;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia [J] . Miller P. Elliott, Martin Seth S., Joshi Parag H., Clinical therapeutics . 2016,第3期

机译：与普伐他汀40 mg相比，匹伐他汀4 mg与普伐他汀40 mg相比可显着更大程度地减少残余脂蛋白胆固醇：来自原发性高脂血症或混合血脂异常患者的短期IV期PREVAIL US试验结果
2. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia [J] . Miller P. Elliott, Martin Seth S., Joshi Parag H., Clinical therapeutics . 2016,第3期

机译：与普伐他汀40毫克相比，岩伐沙汀4毫克提供了显着更大的脂蛋白胆固醇胆固醇：短期阶段IV的结果占原发性高脂血症或混合血脂血症患者的美国试验
3. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (Combined) dyslipidemia: A phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial [J] . SponsellerC.A., MorganR.E., KryzhanovskiV.A., Clinical therapeutics . 2014,第8期

机译：匹伐他汀4 mg与普伐他汀40 mg对原发性高脂血症或混合（合并）血脂异常的成年人的降脂作用比较：IV期，前瞻性，US，多中心，随机，双盲，优势试验
4. Influences of age sex and LDL-C change on cardiovascular risk reduction with pravastatin treatment in elderly Japanese patients: A post hoc analysis of data from the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE) [O] . Yasuyoshi Ouchi, Yasuo Ohashi, Hideki Ito, 2006

机译：年龄性别和LDL-C变化对普伐他汀治疗对老年日本患者的心血管风险降低的影响：普伐他汀抗动脉粥样硬化试验（PATE）的事后分析
5. SHORT-TERM AND LONG-TERM EFFECTS OF PITAVASTATIN AND SIMVASTATIN ON FASTING PLASMA GLUCOSE IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AND ge;2 RISK FACTORS FOR CORONARY HEART DISEASE [O] . Kryzhanovski Vladimir, Eriksson Mats, Hounslow Neil, 2012

机译：Pitavastatin和Simvastatin对原发性高脂血症或混合性血脂异常且≥2冠心病危险因素的空腹血浆葡萄糖的短期和长期影响

PITAVASTATIN 4 MG PROVIDES SIGNIFICANTLY GREATER REDUCTION IN LDL-C COMPARED TO PRAVASTATIN 40 MG WITH NEUTRAL EFFECTS ON GLUCOSE METABOLISM: PRESPECIFIED SAFETY ANALYSIS FROM THE SHORT-TERM PHASE 4 PREVAIL US TRIAL IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

著录项

引文网络

相似文献

相关主题

期刊订阅